Vol 14, No 2 (February 28, 2025): Gland Surgery

Original Article

Post-treatment patient satisfaction in early-stage breast cancer: comparison of cryoablation versus breast conservation therapy using BREAST-Q
Kizuki Matsumoto, Yuko Asano, Hiroki Matsui, Eisuke Fukuma
Gland Surgery  
2025;
14
(2)
:118-128
.
Cohort study comparing volume replacement oncoplastic breast surgery with standard wide local excision for breast cancer
Akriti Nanda, Anisha Chopra, Hibatullah Abuelgasim, Pankaj Gupta Roy
Gland Surgery  
2025;
14
(2)
:129-138
.
Development and application of primary rat parathyroid cells for transplantation in hypoparathyroidism
Ke Ma, Zeyu Yang, Yinde Huang, Supeng Yin, Yizeng Sun, Weihua Wang, Tingjie Yin, Junping Zhu, Chunmeng Shi, Fan Zhang
Gland Surgery  
2025;
14
(2)
:139-152
.
Ultrasound-guided thermal ablation therapy for papillary thyroid carcinoma: a bibliometric analysis from 2000 to 2023
Junping Zhang, Shanshan Li, Mengya Zhu, Wen Chen, Anqi Huo, Yuanyuan Deng, Fang Lu, Ying Liu, Jixiong Xu
Gland Surgery  
2025;
14
(2)
:153-162
.
Safety and feasibility of robotic reoperation via a bilateral axillo-breast approach for patients with locally recurrent thyroid cancer: a single-center retrospective study
Sijuan Chen, Xianjiao Cao, Gaoyuan Xu, Dan Wang, Dayong Zhuang, Peng Zhou, Tao Yue, Qingqing He, Xiaolei Li
Gland Surgery  
2025;
14
(2)
:163-171
.
Video-assisted submuscular breast reconstruction: evaluating a novel technique in high-risk patients
Leonardo Barellini, Simone Miccoli, Benedetta Daicampi, Pietro Susini, Ishith Seth, Mirco Pozzi, Roberto Cuomo, Luca Grimaldi, Gianluca Marcaccini
Gland Surgery  
2025;
14
(2)
:172-178
.
Prognostic analysis of N3 locally advanced breast cancer according to the 8th edition of AJCC clinical stage: a propensity-matched SEER analysis
Qingyun Li, Yanhua Wu, Sihua Lu, Wenxiong Nong, Zhidong Wu, Wanwang Liang, Yunbo Luo
Gland Surgery  
2025;
14
(2)
:179-195
.
Status of thyroid surgery-related medical disputes in China
Peiliang Zhao, Lin Chen, Zhaoyue Li, Bin Luo
Gland Surgery  
2025;
14
(2)
:196-206
.
Assessing neoadjuvant treatment response through serum human epidermal growth factor receptor 2 (HER2) dynamics
Xuliren Wang, Min Xiong, Zhibo Shao, Bingqiu Xiu, Qi Zhang, Douwaner Liu, Weiru Chi, Liyi Zhang, Ming Chen, Hengyu Ren, Zhi-Ming Shao, Jiajian Chen, Jiong Wu
Gland Surgery  
2025;
14
(2)
:207-218
.
Efficacy and safety analysis of a docetaxel-plus-trastuzumab regimen in patients with early-stage HER2-positive breast cancer: a retrospective single-arm study
Jia Yao, Yaqun Zhang, Mingyi Chen, Toshinari Yamashita, Yu Liu, Shusen Zheng
Gland Surgery  
2025;
14
(2)
:219-227
.
DCE-MRI-based machine learning model for predicting axillary lymph node metastasis in breast cancer
Qian Zhang, Yang Lou, Xiaofeng Liu, Chong Liu, Wenjuan Ma
Gland Surgery  
2025;
14
(2)
:228-237
.

Editorial Commentary

Nerve coaptation in deep inferior epigastric perforator (DIEP) flap breast reconstruction
Edward T. C. Dong, Jérôme Martineau, Carlo M. Oranges
Gland Surgery  
2025;
14
(2)
:238-241
.
Insights on preliminary outcomes of a prospective study examining innervation of deep inferior epigastric perforator flaps in autologous breast reconstruction
Joani Christensen, Edward I. Chang
Gland Surgery  
2025;
14
(2)
:242-245
.
The level of estrogen receptor (ER) expression and the length of adjuvant hormonal therapy in ER positive breast cancer
Athina Stravodimou, Ioannis A. Voutsadakis
Gland Surgery  
2025;
14
(2)
:246-251
.
Racial disparities in triple-negative breast cancer: insights from the E5103 trial and beyond
Mika Nashimoto, Akihiko Ozaki
Gland Surgery  
2025;
14
(2)
:252-256
.
Is adjuvant olaparib standard of care in all high-risk HER2-negative early breast cancer presenting gBRCA1/2 mutations?
Pierre Foidart, Guy Jerusalem
Gland Surgery  
2025;
14
(2)
:257-262
.
Stepped-wedge clinical trials in pancreatic cancer: a step backward in improving overall survival or a leap forward to enhance quality of care?
Mauro Daniel Spina Donadio, Victor Hugo Fonseca de Jesus
Gland Surgery  
2025;
14
(2)
:263-267
.